Vertex Pharmaceuticals has received a “Moderate Buy” consensus from 29 brokerages, with most analysts either holding or ...

Sales of the ground-breaking cystic fibrosis (CF) drug Kaftrio was the main driver behind revenues of a Dublin unit of Vertex Pharmaceuticals surging to $2.63bn (€2.26bn) last year. New accounts show ...

In this week’s edition of InnovationRx, we look at health insurers' vows to improve prior authorization, Bell Labs’ IP ...

The American Diabetes Association's McCormick Place event was also a bit of a coming out party for North Chicago-based Abbott ...

Analysts remain bullish on Vertex Pharmaceuticals as HC Wainwright reaffirmed its buy rating with a $550 price target.

Researchers at Vertex Pharmaceuticals in Boston say a single infusion of stem cell-based treatment could be a permanent ...

This was the stock's second consecutive day of gains.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex ...

A cure for diabetes has been top of mind for many that live with the conditions under the term’s umbrella. But type 1 diabetes, in particular, is an irreversible lifelong autoimmune condition. But new ...

TUESDAY, June 24, 2025 (HealthDay News) — A single infusion of a new stem cell-based treatment may have helped 10 out of 12 ...

CHICAGO -- Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and ...